FMF was thought to be a rare disease in Japan until quite recently. Although a few cases were diagnosed by MEFV gene analysis, there has been a proliferation of individual FMF case reports from Japan (9) (10) (11) (12) (13) (14) . In this issue, Nakamura et al report a 34-year-old Japanese female FMF patient with heterozygous E148Q/M694I mutation (15) . Interestingly, E148Q heterozygous mutation seems to enhance the FMF clinical symptoms of M694I heterozygous phenotype in her pedigree analysis (15) .
The role of E148Q in FMF is controversial (16) (17) (18) . As there is a high prevalence of E148Q in normal controls (3-10%), especially in the Japanese population (16%) (19) and no significant differences between the FMF group and control group in the E148Q rate, E148Q is thought to be a benign polymorphism and not a disease-causing mutation. However, this case lead us to consider that E148Q has a phenotypic effect in a compound heterozygote with a severe mutation (ie. M694).
Colchicine is the standard drug for FMF therapy (1, 8) . Colchicine effectively prevents acute attacks and amyloidosis by modulating cytokine production derived from PMN, inhibiting leukocyte chemotaxis, changing the expression of adhesion molecules on the vascular endothelium and PMN, and preventing the extracellular assembly of amyloid subunits into mature amyloid fibrils (8) . Due to the adverse effects of colchicines, like diarrhea, pancytopenia, myopathy, and rash, physicians have discontinued giving it to FMF patients. Many other drugs for FMF, such as interferon alpha, thalidomide, reserpine, prazosin hydrochloride (20) , and herbal medicine (19) have been reported to date (8) . Because of the side effects, Nakamura et al tried to use azelastine, an anti-allergic drug in this patient rather than colchicine, and azelastine successfully reduced the frequency and degree of the attacks (15) . As it is similar to colchicine in function in that it inhibits neutrophil chemotaxis and has less adverse effects, azelastine may be one of the promising drugs for FMF.
Recently Japanese physicians have recognized hereditary periodic fever syndromes as one of the differential diagnoses of unknown fever in Japanese patients. In addition to FMF, recently there were three reports of Japanese TRAPS patients and pedigrees (21) (22) (23) . Since the clinical symptoms and the location of mutations in the patients with Japanese hereditary periodic fever syndromes might differ from those in patients from other countries, it is important for us to accumulate clinical cases to elucidate the mechanisms of hereditary periodic fever syndromes.
